Inhibition of cholesteryl ester transfer protein (CETP) has been proposed as a strategy to raise HDL cholesterol levels. We conducted a single-blind, placebo-controlled study to examine the ...

Another HDL-raising CETP inhibitor has failed to demonstrate cardiovascular benefit in a large clinical trial. With the presentation of the dal-OUTCOMES trial at the American Heart Association in ...

Yet, the Framingham Heart Study showed that raising HDL-c had even better potential in reducing CV events. Could inhibiting CETP in heart patients with lipid abnormalities mimic the situation seen ...

Within the past few years, a class of drugs known as cholesteryl ester transfer protein (CETP) inhibitors have been under investigation for their potential to increase HDL-C levels and, in effect ...

Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. A total of 1623 patients ...

Having low CETP leads to high HDL levels in your blood, but it doesn't seem to increase the risk of heart disease. Certain inherited conditions, like familial hyperalphalipoproteinemia and ...

"We discovered that the CETP's N-terminal penetrates HDL and its C-terminal interacts with LDL forming a ternary complex. Structure analyses lead us to hypothesize that the interaction may ...

Medically reviewed by Rafle Fernandez, MD A low high-density lipoprotein (HDL) cholesterol level can increase your risk of ...

This is one of our periodic Five Year Watch columns, examining whether and why predictions of scientific progress were accurate, or hype. Five years ago, a new class of cholesterol-lowering ...

Interconversion between lipid-free apolipoprotein AI, discoid lipid-poor pre-β-HDL, spherical small, dense HDL3, and large, light HDL2 mediated by lecithin:cholesterol acyltransferase ...